WINSTON-SALEM, N.C., Oct. 19 /PRNewswire/ -- Pilot Therapeutics Inc., a Nutritional Therapeutics Innovation Company, today announced the appointment of Ross Consaul as CEO and Keith Wakeman as President.
"Pilot has always had promising technology and patents in the food, medical food and dietary supplement areas with over 60 issued and pending patents. These new additions will unlock the potential to rapidly move our world class technologies and IP to the marketplace," said Dr. Floyd "Ski" Chilton, Founder and Chief Technology Officer of Pilot Therapeutics Inc.
Ross joins Pilot with over 20 years experience leading New Ventures, R&D, and New Product Development for large and small companies including Bayer, Kellogg, Pizza Hut and Kashi. He was most recently Nutrition General Manager for Bayer BioScience where he was responsible for identifying and creating new health and nutrition businesses for Bayer.
Keith brings over 20 years of management experience in the food and nutrition industry leading Marketing, Innovation and New Ventures organizations for major companies including Kellogg, Keebler and Nabisco. He was most recently President of Cherry Street Innovation LLC, an innovation company he founded to identify and develop new growth platforms through new ventures and brand innovation.
Former President Scott Derks will remain with Pilot as Vice President, Operations.
"Collectively, Ross and Keith have created new businesses generating nearly $3 billion revenue and bring tremendous experience in health and nutrition. We are delighted to welcome them to our team," said Chilton.
Pilot Therapeutics is a Nutritional Therapeutics Innovation Company dedicated to the prevention and treatment of chronic inflammatory diseases. Through its Functional Liponomics(TM) discovery platform, Pilot examines the influence of fatty acids on the expression of genes that control the inflammatory and allergic process. Utilizing this technology Pilot has developed a pipeline of medical foods for the prevention and treatment of numerous chronic inflammatory disorders in humans and animals. These innovative products are based on over 60 issued and pending domestic and international patents.
Pilot Therapeutics was founded by Chilton, professor of physiology and pharmacology at Wake Forest University School of Medicine. Chilton is also director of the Wake Forest and Brigham and Women's Program for Botanical Lipids which is supported by a $7.5 million grant from the National Center for Complementary and Alternative Medicine and the Office of Dietary Supplements.
|SOURCE Pilot Therapeutics Inc.|
Copyright©2007 PR Newswire.
All rights reserved